Stay updated with breaking news from Dose Modifications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Additional analyses of DESTINY-Breast03 trial of ENHERTU and updated results from triple negative breast cancer cohort of TROPION-PanTumor01 trial of datopotamab deruxtecan to be highlighted Daiichi
Daiichi Sankyo Company, Limited: Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer ii 80% (n=64) CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response i Includes patients with =1 postbaseline scan or who discontinued treatment. ii ORR is CR+PR; Responses are confirmed (CRs/PRs; n=32) plus those CRs/PRs too early to be confirmed (n=5). iii DCR is CR+PR+SD iv Preliminary PFS limited by earlier censoring b...
Daiichi Sankyo Company, Limited: ENHERTU Receives Prime Minister's Award from the Japan Techno-Economics Society Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Minister's Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with the objective of contributing to the development of the nation's economy, social changes, and the pr...
Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca's ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. This press release features multimedia. View the full release here: https://www.businesswire.com/...